Orsted Names Rasmus Errboe Deputy CEO and Chief Commercial Officer
By Dominic Chopping
Orsted is establishing a new commercial organization under Rasmus Errboe, who is appointed deputy chief executive and chief commercial officer, as it continues to shuffle its executive team amid challenging conditions in the wind industry.
The Danish renewable-energy company has been struggling with surging costs at some of its offshore development projects as supplier delays, higher funding costs, and insufficient government subsidies have seen some projects become unfeasible.
Last month it launched a comprehensive new plan with cost cuts, a pause in dividends, asset sales and new business priorities and appointed a new chief financial officer and chief operating officer.
Following the launch of its new business plan, Orsted said it is now simplifying its executive management structure to further sharpen its focus on project execution, financial discipline, value creation, and risk management.
Orsted said it will keep its organizational set-up with three regions, but going forward, the regional CEOs, the head of global stakeholder relations, and the head of strategy, portfolio, innovation & digital will report to the new commercial organization under Rasmus Errboe.
Errboe is currently interim chief financial officer and was previously chief executive of region Europe at Orsted. He will start his new role on April 1.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
March 21, 2024 09:18 ET (13:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth